Dermatology Update 2018 FALL

SESSIONS & ABSTRACTS

MONTREAL, FAIRMONT THE QUEEN ELIZABETH - NOVEMBER 15-18, 2018

Efficacy and safety of alitretinoin in the treatment of skin diseases other than hand eczema

Alitretinoin (9-cis retinoic acid) is a pan retinoic acid agonist that binds and transactivates RAR and RXR receptors. It was initially used as 0.1% gel and orally in the management of Kaposi’s sarcoma at relatively high doses. At present, the use of systemic alitretinoin has proved extremely efficacious in the management of recalcitrant chronic hand eczema. Furthermore, there have been other retinoid-responsive dermatosis including pityriasis rubra pilaris, mycosis fungoides, keratitis-ichthyosis-deafness (KID) syndrome, lichen planus, etc. that have demonstrated remission post usage of systemic alitretinoin.

With a better toxicity profile, compared to the other systemic retinoids, alitretinoin could be considered a valuable treatment option in the near future for the treatment of several dermatologic disorders especially in women of child-bearing age.

PART OF THE EVENT

Missing Event Data
Dr. Ivan Litvinov

Dr. Ivan Litvinov

Dermatologist, Montreal, QC

Actelion - Dermatology Update Sponsor